美股市场个股详情

IMMX Immix Biopharma

添加自选
  • 2.300
  • +0.170+7.98%
收盘价 04/23 16:00 (美东)
  • 2.440
  • +0.140+6.09%
盘前 07:00 (美东)
6071.18万总市值-2584市盈率TTM
盘前分时
  • 5日
  • 日K
  • 周K
  • 月K
  • 季K
  • 年K

资金分布

单位: --

资金流向

实时日周月

暂无数据

新闻

评论

    Trytosaveabit
    Trytosaveabit
    04/19 04:13

    News

    $Immix Biopharma(IMMX.US)$ Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
    MT Newswires· 1 min ago
    Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation visits at US testing locations this month and May.
    The open-label, phase 1b dose-expansion trial is expected to enroll around 40 patients with adequate cardia...
    Jaguar8
    Jaguar8
    04/15 21:37
    $Immix Biopharma(IMMX.US)$
    NEWS
    Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
    LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated...
    Trytosaveabit
    Trytosaveabit
    03/20 22:03

    Update

    $Immix Biopharma(IMMX.US)$ Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
    Trytosaveabit
    Trytosaveabit
    02/09 05:50

    Nice

    $Immix Biopharma(IMMX.US)$ Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
    5 MINUTES AGO, 4:45 PM EST
    VIA GLOBENEWSWIRE
    Trytosaveabit
    Trytosaveabit
    02/07 18:01

    Update

    $Immix Biopharma(IMMX.US)$
    LOS ANGELES, February 5, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock. ImmixBio has granted the underwriters a 30-day option to purchase up to 783,970 additional sha...
    2
阅读更多

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议
美股
综合热度
股票代码
最新价
涨跌幅